Print Page  Close Window

Investors

Corporate Profile

Founded in 2006, Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye.

The foundation of Ocular Therapeutix's pipeline is based on its proprietary, bioresorbable hydrogel technology that uses polyethylene glycol, or PEG, as a key component. The most advanced product candidate, currently in Phase 3 clinical development, is a drug-eluting intracanalicular depot containing the ste... More >>

Stock QuoteMore >>
OCUL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$9.12
Change (%) Stock is Down 1 (9.88%)
Volume436,784
Data as of 02/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
 
Investor EventsMore >>
DateTitle
02/23/17 9:00 a.m. ET
Ocular Therapeutix, Inc. at the 2017 RBC Capital Markets Global Healthcare Conference
LocationThe New York Palace Hotel, New York, NY
Industry EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Ocular Therapeutix, Inc. posts new information to the site.
Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.